Northeast Pharmaceutical Group Co Ltd (000597.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE0000009G0
Northeast Pharmaceutical Group Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 7.50 bn CNY | 7.07 bn CNY |
| Gross profit | 2.76 bn CNY | 2.64 bn CNY |
| Operating income | 577.76 m CNY | 498.81 m CNY |
| EBIT | 475.95 m CNY | 354.43 m CNY |
| Net income | 409.85 m CNY | 260.07 m CNY |
| Diluted EPS – continuing operations | 0.29 CNY | 0.18 CNY |
Full history since 1993, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali hydrochloride, chloramphenicol, and other products; and reproductive system and hormone products comprising carboprost suppositories, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. It also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; narcotics and psychotropic drugs and related products, including morphine hydrochloride injections and tablets, oxycodone hydrochloride injection, compound glycyrrhiza series, and acetaminophen-codeine tablets; anti-AIDS products comprising Krughar /zidovudine tablets and capsules, efavirenz tablets, and other products; and in vitro biological diagnostic reagent products for HIV, HBV, HCV, HPV, and TB. In addition, it offers general health products, including glucosamine sulfate chondroitin collagen D3 calcium capsules, protein powder, probiotic powder, effervescent tablets, chewable tablets, solid drinks, and other products. Further, it provides Enterogermina, magnesium aluminum carbonate chewable tablets; compound proglutamine-cimetidine tablets; acetaminophen tablets; pain relievers, phenacetin, pregabalin, noscapine syrup, and citrate table; and other products, as well as cell therapy products. Additionally, it engages in medical distribution business. The company was founded in 1946 and is based in Shenyang, China.
More stocks
- Shanghai Action Education Technology CO.LTD. (605098.SS)
- Asseco South Eastern Europe SA (ASE.WA)
- Jiangsu Longda Superalloy Co. Ltd. A (688231.SS)
- Pegavision (6491.TW)
- GuoChuang Software Co Ltd (300520.SZ)
- Shenzhen Best of Best Holdings Co. Ltd. A (001298.SZ)
- Arcadyan Technology Corp (3596.TW)
- Guangdong Sky Dragon Printing Ink Group Co Ltd (300063.SZ)
- Young & Co's Brewery PLC (YNGA.L)
- Jiangsu Tongxingbao Intelligent Transportation Technology Co. Ltd. A (301339.SZ)
- Akasha Wira International Tbk (ADES.JK)
- IP Group PLC (IPO.L)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.